S
Serdar M. Dursun
Researcher at University of Alberta
Publications - 197
Citations - 6896
Serdar M. Dursun is an academic researcher from University of Alberta. The author has contributed to research in topics: Schizophrenia & Schizophrenia (object-oriented programming). The author has an hindex of 38, co-authored 188 publications receiving 5670 citations. Previous affiliations of Serdar M. Dursun include Halifax & University of São Paulo.
Papers
More filters
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.
Journal ArticleDOI
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
J.F. William Deakin,Jane Lees,Shane McKie,Jaime Eduardo Cecílio Hallak,Steve R. Williams,Serdar M. Dursun +5 more
TL;DR: The results are compatible with the theory that the neural and subjective effects of ketamine involve increased glutamate release and may underpin 2 fundamental processes of psychosis: abnormal perceptual experiences and impaired cognitive-emotional evaluation of their significance.
Journal ArticleDOI
Cannabidiol for the treatment of psychosis in Parkinson’s disease
Antonio Waldo Zuardi,José Alexandre de Souza Crippa,Jaime Eduardo Cecílio Hallak,Joel Porfirio Pinto,Marcos Hortes Nisihara Chagas,Guilherme Riccioppo Rodrigues,Serdar M. Dursun,Vitor Tumas +7 more
TL;DR: In this paper, the authors evaluated the efficacy, tolerability and safety of CBD on patients with Parkinson's disease with psychotic symptoms and found that CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale.
Journal ArticleDOI
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Imran B Chaudhry,Jaime Eduardo Cecílio Hallak,Nusrat Husain,Fareed Aslam Minhas,John D. Stirling,Paul Richardson,Serdar M. Dursun,Graham Dunn,Bill Deakin +8 more
TL;DR: The addition of minocycline to TAU early in the course of schizophrenia predominantly improves negative symptoms, and this is mediated by neuroprotective, anti-inflammatory or others actions.
Journal Article
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
TL;DR: In this article, the authors established specific criteria by which selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome may be identified, which are 2 or more of the following symptoms developing within 1 to 7 days of discontinuation or reduction in dosage of an SSRI after at least 1 month's use.